Eli Lilly (LLY): FY24 Q3 earnings call, Oct 30, 2024
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Oct 30, 2024 earnings call (FY24 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
5 matches for “Alzheimer”; 5 quoted, at least 25 words apart.
…Kisunla in Japan and Great Britain for the treatment of early symptomatic Alzheimer's disease. Disclosure of positive 176-week data from the SURMOUNT-1 Phase 3 study…
…recent medical congresses. Starting with neuroscience. Yesterday, at the clinical trials in Alzheimer's Disease Conference, we are pleased to share positive results from our Phase…
…donanemab where we are trying to reduce the risk of progressions symptomatic Alzheimer's disease. In this upcoming Phase 3 registrational trial called TRAILRUNNER 3, we…
…GlcNAcase anti-tau agent. While neither dose slowed clinical decline in early symptomatic Alzheimer's disease, biomarker data suggests potential impacts on tau pathology, brain volume and…
…Ebglyss for moderate-to-severe atopic dermatitis in the U.S., Kisunla for early symptomatic Alzheimer's disease in Japan and Great Britain, and positive data disclosures for Phase…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2024-10-30:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2024-10-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP